- Home
- URGN vs FMBH Comparison
URGN vs FMBH Comparison
Compare URGN & FMBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- FMBH
- Stock Information
- Founded
- URGN 2004
- FMBH 1865
- Country
- URGN United States
- FMBH United States
- Employees
- URGN N/A
- FMBH N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- FMBH Major Banks
- Sector
- URGN Health Care
- FMBH Finance
- Exchange
- URGN Nasdaq
- FMBH Nasdaq
- Market Cap
- URGN 904.0M
- FMBH 974.1M
- IPO Year
- URGN 2017
- FMBH N/A
- Fundamental
- Price
- URGN $18.79
- FMBH $39.40
- Analyst Decision
- URGN Strong Buy
- FMBH Hold
- Analyst Count
- URGN 8
- FMBH 5
- Target Price
- URGN $28.50
- FMBH $43.40
- AVG Volume (30 Days)
- URGN 1.1M
- FMBH 65.0K
- Earning Date
- URGN 11-05-2025
- FMBH 10-30-2025
- Dividend Yield
- URGN N/A
- FMBH 2.54%
- EPS Growth
- URGN N/A
- FMBH 13.11
- EPS
- URGN N/A
- FMBH 3.52
- Revenue
- URGN $94,238,000.00
- FMBH $328,480,000.00
- Revenue This Year
- URGN $39.63
- FMBH N/A
- Revenue Next Year
- URGN $111.49
- FMBH $4.33
- P/E Ratio
- URGN N/A
- FMBH $11.19
- Revenue Growth
- URGN 10.85
- FMBH 7.81
- 52 Week Low
- URGN $3.42
- FMBH $27.58
- 52 Week High
- URGN $21.71
- FMBH $43.86
- Technical
- Relative Strength Index (RSI)
- URGN 48.50
- FMBH 49.45
- Support Level
- URGN $18.45
- FMBH $39.63
- Resistance Level
- URGN $21.71
- FMBH $40.21
- Average True Range (ATR)
- URGN 1.18
- FMBH 0.75
- MACD
- URGN -0.18
- FMBH -0.10
- Stochastic Oscillator
- URGN 17.51
- FMBH 4.69
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About FMBH First Mid Bancshares Inc.
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.